Hugel global botulinum toxin sales rise forty-six percent in H1 2026

Hugel's first-half 2026 botulinum toxin sales rose 46.6% year-on-year to KRW 149.4 billion, signaling that the manufacturer is successfully scaling its global footprint, particularly in the Americas where toxin sales more than doubled. For aesthetic clinics, this rapid expansion translates to a highly active, well-funded alternative in the neurotoxin market as Hugel builds out its presence. The company's overall consolidated sales for the first half of 2026 grew 27.2% to KRW 254.5 billion, while operating profit rose 8.4% to KRW 103.7 billion. Although second-quarter sales reached a record KRW 137.9 billion, operating profit for that quarter dipped slightly by 1.1% to KRW 56 billion. This dip reflects Hugel’s heavy financial investments in direct sales and marketing infrastructure in the United States. Additionally, its cosmetics and other segments grew 31.7% to KRW 39 billion in the first half of 2026. As Hugel continues to fund its US commercialization push, clinicians can expect aggressive account support, promotional pricing, and direct sales outreach from representatives looking to challenge established market leaders.

Source: Global Cosmetics News, https://globalcosmeticsnews.com/hugel-posts-record-h1-as-global-aesthetics-and-cosmetics-sales-accelerate/